Phase I Study of Intravenous Artesunate for Solid Tumors
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase One study to determine the safety, tolerability, and maximum tolerated dose
of intravenous artesunate in patients with solid tumors. A rapid dose escalation design will
be used, in which single patients will be enrolled to escalating dose levels until a grade 2
or higher toxicity occurs during cycle 1. Enrollment will then continue using 3 to 6 patients
at each dose level until a dose is reached at which 2 or more patients out of 6 experience a
treatment-related toxicity.